NCT06825949Not yet recruitingNot Applicable
A Phase II Single-Arm Clinical Study to Explore the Efficacy and Safety of Hyperbaric Oxygen in the Neoadjuvant Treatment of Hormone Receptor Positive Breast Cancer Patients
Guangdong Provincial People's Hospital1 site in 1 country55 target enrollmentStarted: February 15, 2025Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Enrollment
- 55
- Locations
- 1
- Primary Endpoint
- RCB 0/1 rate
Study Overview
Brief Summary
The goal of this study is to explore the efficacy and safety of hyperbaric oxygen in the neoadjuvant treatment of hormone receptor positive breast cancer patients
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 60 Years (Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •understood the study process, volunteered to participate in this study and signed an informed consent form
- •Patients with histopathologically confirmed diagnosis of initial unilateral primary invasive breast cancer, occult breast cancer, Inflammatory breast cancer and eczema-like carcinoma are excluded.
- •Female, aged ≥ 18 years and ≤ 60 years.
- •Patients who meet the inclusion criteria of neoadjuvant therapy to receive neoadjuvant therapy for breast cancer (locally advanced breast cancer (AJCC Stage III, except T3N1M0), or operable, but do not meet the conditions of breast conservation or axillary preservation (Stage IIA-IIB and T3N1M0).
- •Hormone receptor-positive breast cancer (Luminal/HER2-low (IHC 2+/FISH-negative)).
- •ECOG performance status 0-
- •LVEF ≥ 55 per cent
- •Adequate bone marrow functional reserve: white blood cell count ≥ 3.0 x 109/L, neutrophil count ≥ 1.5 x 109/L; platelet count ≥ 100 x 109/L; haemoglobin ≥ 90g/L;
- •AST, ALT ≤ 2.5 times the upper limit of normal value, alkaline phosphatase ≤ 2.5 times the upper limit of normal value, total bilirubin ≤ 1.5 times the upper limit of normal value; serum creatinine ≤ 1.5 times the upper limit of normal value
- •For non-menopausal or non-surgically sterilised female patients: consent to contraception during treatment and for at least 7 months after the last dose of study treatment
Exclusion Criteria
- •have contraindications to hyperbaric oxygen therapy: lung disease (severe chronic obstructive airway disease, herpetic lung disease, acute or chronic lung infections, uncontrolled asthma, untreated pneumothorax), previous history of middle ear surgery, middle ear disease (eustachian tube dysfunction\recurrent vertigo), eye disease (retinal detachment).
- •Previous hyperbaric oxygen therapy.
- •Distant metastases, including lymph node metastases in the contralateral breast and mediastinum.
- •Malignancy other than radically treated basal or squamous cell carcinoma of the skin or CIS of the uterine cervix within the last two years.
- •Pregnancy or lactation.
- •Uncontrolled hypertension, cardiac, hepatic, renal related diseases or other medical or psychiatric disorders.
- •Major surgical procedures unrelated to breast cancer within 4 weeks prior to randomisation, or patients who have not fully recovered from such surgical procedures.
- •Serious or uncontrolled infections that may interfere with study treatment or assessment of study results, including but not limited to active hepatitis virus infection, human immunodeficiency virus (HIV) antibody positivity, pulmonary infection, or other infections.
Arms & Interventions
Hyperbaric Oxygen group
Experimental
Patients who meet the inclusion criteria will be enrolled and given hyperbaric oxygen intervention, with a minimum of 5 times hyperbaric oxygen treatments per chemotherapy cycle, one per day for 60-90 minutes, for a total of 30-40 hyperbaric oxygen treatments (100% oxygen at a pressure of 2.0 ATA).
Intervention: Hyperbaric oxygen treatment (Device)
Outcomes
Primary Outcomes
RCB 0/1 rate
Time Frame: After completion of standard cycle of neoadjuvant therapy (through study completion, an average of half a year)
Secondary Outcomes
- The Miller and payne classification(After completion of standard cycle of neoadjuvant therapy (through study completion, an average of half a year))
- pCR rate after hyperbaric oxygen combined with neoadjuvant therapy in breast cancer patients(After completion of standard cycle of neoadjuvant therapy (through study completion, an average of half a year))
- Number of participants with treatment-related adverse events as assessed by CTCAE v5.0(through study completion ( an average of half a year))
- RECIST criteria(After completion of the first cycle of adjuvant therapy, After completion of standard cycle of neoadjuvant therapy (through study completion, an average of half a year))
- Life quality (EORTC QLQ C-30、EORTC QLQ BR-23 questionnaire)(At the time of patient enrolment, Each cycle of chemotherapy (8 cycle, each cycle is 3 weeks) , Day before surgery, 3 months after surgery)
- Side effects of hyperbaric oxygen therapy(during the hyperbaric oxygen therapy (up to half a year))
- the Tumor immune microenvironment of the Hyperbaric Oxygen Therapy and neoadjuvant therapy(the time when the patient enrollment, at the end of the first cycle of neoadjuvant therapy (at about the first month) , surgery)
Investigators
Kun Wang
Professor
Guangdong Provincial People's Hospital
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Phase 1
A Phase II Single-Arm Clinical Study to Explore the Efficacy and Safety of Hyperbaric Oxygen in the Neoadjuvant Treatment of Breast Cancer PatientsBreast CancersNCT06811870Guangdong Provincial People's Hospital161
Unknown
Phase 2
IXO (Irinotecan, Xeloda, Oxaliplatin) in Rectal CancerRectal CancerNCT01237665Ottawa Hospital Research Institute15
Recruiting
Phase 2
Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLCNon Small Cell Lung CancerNCT04875585Medical University Innsbruck33
Not yet recruiting
Phase 2
A Study to Evaluate the Efficacy and Safety in Subjects With Advanced Breast Cancer Treated With SYHX2011Advanced Breast CancerNCT06354114CSPC Ouyi Pharmaceutical Co., Ltd.80
Withdrawn
Phase 2
Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Eribulin Chemotherapy (ACE) in Operable HER2-negative Breast CancerBreast CancerNCT02215876Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins